Term
| Results from a triphasic reaction of distal digits to cold or emotion, in which the skin color changes from white to blue to red |
|
Definition
|
|
Term
| most common skin sign of lupus |
|
Definition
|
|
Term
| bilateral arthritis without joint deformity; swelling and tenderness must be present |
|
Definition
| Musculoskeletal clinical sign of lupus |
|
|
Term
| Caused by disruption of blood flow to bone and prednisone therapy |
|
Definition
|
|
Term
| Hematuria, Proteinuria, Casts |
|
Definition
| Kidney clinical signs of lupus |
|
|
Term
| clot formation in a critical vessel that supplies blood to the spinal cord |
|
Definition
| rare clinical presentation in lupus |
|
|
Term
|
Definition
| frequent in lupus from chronic inflammation or medication-related hemorrhage |
|
|
Term
| appears to be mediated by anti-platelet antibodies and/or antiphospholipid antibodies |
|
Definition
|
|
Term
| Disease and medication (immunosuppressants) related |
|
Definition
|
|
Term
| most common manifestation of pulmonary involvement |
|
Definition
|
|
Term
| seen in SLE patients with nephritic syndrome, infection, and/or cardiac failure |
|
Definition
|
|
Term
| fever, dyspnea, cough w/ scanty sputum, hemoptysis, tachypnea and pleuritic chest pain |
|
Definition
|
|
Term
| most common CV clinical presentation in lupus |
|
Definition
|
|
Term
| very similar features to viral myocarditis |
|
Definition
| Myocarditis clinical presentation in SLE |
|
|
Term
| many flat reddish-tan vetations spreading overal mitral valve and chordate |
|
Definition
|
|
Term
| Esophagitis, dysphagia, nausea, vomiting |
|
Definition
| most cases are medication related |
|
|
Term
| some GI/Liver Clinical Presentations of SLE |
|
Definition
| Chronist intestinal pseudo-obstruction, mesenteric vasculitis, protein-losing enteropathy, pancreatitis, lupus hepatitis |
|
|
Term
| must be screened every 6 months if taking the antimalarial medications |
|
Definition
|
|
Term
| dry eyes and/or mouth due to exocrine glands infiltrated with lymphocytes |
|
Definition
| Comorbid Sogren's Syndrome |
|
|
Term
| Recurrent arterial and/or venous thrombosis, fetal loss and thrombocytopenia |
|
Definition
| Antiphospholipid Syndrome (APS) |
|
|
Term
| Speckled pattern, 97% of patients |
|
Definition
| Antinuclear Antibody (ANA) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Anti-Smith and Anti-Ro (SSA) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| nonspecific but in combo with positive ANA --> suspect SLE |
|
Definition
| Low compliment (C3 or C4) lab test |
|
|
Term
| echinachea and excessive zinc supplmementation |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| avoid in SLE (unless deglycerided) |
|
|
Term
| Used for patients on chronic NSAIDs |
|
Definition
|
|
Term
| used for mild disease (arthritis) |
|
Definition
|
|
Term
| used for skin and joint manifestations |
|
Definition
| Anti-malarial (hydroxychloroquine) |
|
|
Term
| used for skin and localized discoid lesions |
|
Definition
| topical/intralesional corticosteroids |
|
|
Term
| used for life-threatening or multisystemic organ-threatening manifestations |
|
Definition
| Oral or IV corticosteroids |
|
|
Term
| Standard of practice for lupus nephritis |
|
Definition
| High dose IV corticosteroids |
|
|
Term
| Immunosuppressant primarily used as adjunct therapy to corticosteroids; reduces the number of SLE flares |
|
Definition
|
|
Term
|
Definition
| Useful as a steroid sparing agent in nonrenal disease |
|
|
Term
|
Definition
| For renal and nonrenal symptoms |
|
|
Term
| DMARD to manage arthritis, skin rashes below the neck that are in refractory to topical corticosteroids, endo-/pericarditis, and constitutional symptoms |
|
Definition
|
|
Term
|
Definition
| use with caution in patients with renal disease (medication is eliminated via the kidneys) |
|
|
Term
| B-lymphocyte stimulator-specific inhibitor |
|
Definition
|
|
Term
| Plasmaphoresis, IV immunoglobulin, stem cell transplants, immune therapy |
|
Definition
| reserved for poor responders with severe disease |
|
|
